{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:38Z","timestamp":1784543078722,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jhep.2019.10.020","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T18:09:30Z","timestamp":1572718170000},"page":"441-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Glecaprevir\/pibrentasvir for 8\u202fweeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: The EXPEDITION-8 trial"],"prefix":"10.1016","volume":"72","author":[{"suffix":"Jr","given":"Robert S.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-2443","authenticated-orcid":false,"given":"Lino","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-9293","authenticated-orcid":false,"given":"Vladimir","family":"Chulanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-7435","authenticated-orcid":false,"given":"G\u00e1bor","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elimelech","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Rosado","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rodriguez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Urb\u00e1nek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Abergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-090X","authenticated-orcid":false,"given":"Eric","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra S.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-7314","authenticated-orcid":false,"given":"Gretja","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuhong","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico J.","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Felizarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.10.020_b0005","unstructured":"Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. Available at: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/ (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0010","unstructured":"Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries, March 2018. Geneva, Switzerland: World Health Organization; 2018 (WHO\/CDS\/HIV\/18.4). Licence: CC BY-NC-SA 3.0. Available at: https:\/\/www.who.int\/hepatitis\/publications\/hep-c-access-report-2018\/en\/ (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0015","unstructured":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Available at: https:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2018\/en\/ (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.10.020_b0025","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: https:\/\/www.hcvguidelines.org\/ (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2019.10.020_b0035","doi-asserted-by":"crossref","unstructured":"EASL Recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69:461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"10.1016\/j.jhep.2019.10.020_b0040","unstructured":"Gilead Sciences. Vosevi (sofosbuvir\/velpatasvir\/voxilaprevir) summary of product characteristics. June 2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vosevi-epar-product-information_en.pdf (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0045","unstructured":"AbbVie. Maviret (glecaprevir\/pibrentasvir) summary of product characteristics. July 2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf (accessed July 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0050","unstructured":"AbbVie. Mavyret (glecaprevir\/pibrentasvir) US prescribing information. April 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209394s006lbl.pdf (accessed July 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2019.10.020_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.10.020_b0065","doi-asserted-by":"crossref","first-page":"e01620","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2019.10.020_b0070","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.020_b0075","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2019.10.020_b0080","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.10.020_b0085","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.020_b0090","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.020_b0095","doi-asserted-by":"crossref","unstructured":"Reply to: \u201cSofosbuvir\/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: response to EASL recommendations on treatment of Hepatitis C 2018\u201d: EASL Recommendations on Treatment of Hepatitis C 2018: precision on the treatment of patients with genotype 3a infection and compensated cirrhosis. J Hepatol 2019;70:562\u2013564.","DOI":"10.1016\/j.jhep.2018.11.004"},{"key":"10.1016\/j.jhep.2019.10.020_b0100","unstructured":"Gilead Sciences. Vosevi (sofosbuvir\/velpatasvir\/voxilaprevir) US prescribing information. November 2017. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209195s002lbl.pdf (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0105","unstructured":"AbbVie. Maviret (glecaprevir\/pibrentasvir) summary of product characteristics. August 2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0110","unstructured":"AbbVie. Mavyret (glecaprevir\/pibrentasvir) US prescribing information. September 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209394s008lbl.pdf (accessed September 2019)."},{"key":"10.1016\/j.jhep.2019.10.020_b0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.10.020_b0120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: a randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.020_b0125","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jvh.12853","article-title":"Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection","volume":"25","author":"Sulkowski","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.10.020_b0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jhep.2019.10.020_b0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient\u2019s perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jhep.2019.10.020_b0140","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S2468-1253(17)30053-5","article-title":"Shortening the duration of therapy for chronic hepatitis C infection","volume":"2","author":"Emmanuel","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.020_b0145","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s12325-018-0721-1","article-title":"Development of a comprehensive dataset of hepatitis C patients and examination of disease epidemiology in the United States, 2013\u20132016","volume":"35","author":"Chirikov","year":"2018","journal-title":"Adv Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:38:19Z","timestamp":1759174699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819306476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0168827819306476"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glecaprevir\/pibrentasvir for 8\u202fweeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: The EXPEDITION-8 trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}